About 7 results found for searched term "65-86-1" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5205 | ML204 | Calcium Channel |
| ML204 is a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. | ||
| M5836 | Orotic acid (6-Carboxyuracil) | DNA/RNA Synthesis |
| 6-Carboxyuracil; Vitamin B13 | ||
| Orotic acid(6-Carboxyuracil) is a heterocyclic compound and an acid. | ||
| M29465 | dTAG-47 | PROTAC |
| dTAG-47, heterobifunctional dTAG molecule, targets mutant FKBP12 (FKBP12F36V). FKBP12F36V serves as a degradation tag (dTAG) and is fused to a protein of interest. dTAG-47 can be used for the research of basal-like breast cancers (BBC). | ||
| M4138 | Deucravacitinib (BMS-986165) | JAK |
| BMS986165 | ||
| Deucravacitinib (BMS-986165) is a first-in-class, selective, orally bioavailable inhibitor of TYK2 transitions.Deucravacitinib selectively binds the TYK2 pseudokinase (JH2) structural domain with an IC50 of 1.0 nM and a Ki value of 0.02 nM. Deucravacitinib (BMS-986165) blocks receptor-mediated Tyk2 activation by stably regulating the JH2 structural domain. deucravacitinib also inhibits the IL-12/23 and type I IFN pathways. deucravacitinib may be used in psoriasis research. | ||
| M11354 | INCB086550 | PD-1/PD-L1 |
| PD-1/PD-L1-IN-8 | ||
| INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models. | ||
| M20267 | WAY-650886 | Casein Kinase |
| WAY-650886 is a Casein kinase 1δ inhibitor | ||
| M28688 | PF-06372865 | GABA Receptor |
| Darigabat | ||
| PF-06372865 is an orally active, α2/α3/α5 subtype-selective GABAA positive allosteric modulator (PAM). PF-06372865 is a high affinity ligand at GABAA receptors containing α1/α2/α3/α5 subunits (Kis of 2.9 nM, 21 nM, 134 nM for α2, α1 PAM, α2 PAM, respectively), with low affinity for α4/α6 subunits. PF-06372865 can across the blood-brain barrier (BBB). PF-06372865 has anxiolytic activity and has the potential for epilepsy. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
